Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study

[1]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[2]  R. Payne,et al.  The epidemiology of multimorbidity in primary care: a retrospective cohort study , 2018, The British journal of general practice : the journal of the Royal College of General Practitioners.

[3]  Harry Hemingway,et al.  Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals , 2017, The Lancet.

[4]  J. Hallas,et al.  Hydrochlorothiazide use is strongly associated with risk of lip cancer , 2017, Journal of internal medicine.

[5]  W. Barlow,et al.  Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER–Medicare Population , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[6]  P. Elwood,et al.  Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies , 2016, PloS one.

[7]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[8]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[9]  S. Orlov,et al.  NKCC1 and NKCC2: The pathogenetic role of cation-chloride cotransporters in hypertension , 2015, Genes & diseases.

[10]  D. Ichikawa,et al.  Role of the Na ⁺/K ⁺/2Cl⁻ cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma. , 2014, World journal of gastroenterology.

[11]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[12]  John Chalmers,et al.  Clinical Practice Guidelines for the Management of Hypertension in the Community , 2014, Journal of clinical hypertension.

[13]  A. Schutte,et al.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.

[14]  N. Weiss,et al.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. , 2013, Journal of the National Cancer Institute.

[15]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[16]  Mhs G. Michael Felker.  Diuretic Management in Heart Failure , 2010 .

[17]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[18]  R. Perera,et al.  Adaptation and validation of the Charlson Index for Read/OXMIS coded databases , 2010, BMC family practice.

[19]  G. Michael Felker,et al.  Diuretic management in heart failure. , 2010, Congestive heart failure.

[20]  G. Nahler.  defined daily dose (DDD) , 2009 .

[21]  H. Sørensen,et al.  Use of photosensitising diuretics and risk of skin cancer: a population-based case–control study , 2008, British Journal of Cancer.

[22]  A. Shiozaki,et al.  Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. , 2006, The journal of physiological sciences : JPS.

[23]  G. Giebisch,et al.  Cellular mechanism of the furosemide sensitive transport system in the kidney , 1982, Klinische Wochenschrift.

[24]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[25]  C. Dibben,et al.  The English indices of deprivation 2004 , 2011 .

[26]  Randal K. Wada,et al.  Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[27]  Y. Adam,et al.  Malignant ascites: past, present, and future. , 2004, Journal of the American College of Surgeons.

[28]  A. P. Spencer,et al.  Combined Furosemide and Human Albumin Treatment for Diuretic-Resistant Edema , 2003, The Annals of pharmacotherapy.

[29]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[30]  S. Shankar,et al.  Loop diuretics: from the Na-K-2Cl transporter to clinical use. , 2003, American journal of physiology. Renal physiology.

[31]  H. Sørensen,et al.  Confounding by Indication in Epidemiologic Studies of Commonly Used Analgesics , 2002, American journal of therapeutics.

[32]  H. Atlan,et al.  Overexpression of the Na+/K+/Cl− cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts , 2000, Journal of cellular physiology.

[33]  B. Stricker,et al.  Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.

[34]  W. Faught,et al.  A survey of practice in management of malignant ascites. , 1998, Journal of pain and symptom management.

[35]  S. Gutthann,et al.  Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.

[36]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[37]  L. G. García Rodríguez,et al.  Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.

[38]  Dr. med. Dr. phil. Gerhard Nahler.  Dictionary of Pharmaceutical Medicine , 1994, Springer Vienna.

[39]  C. Greenway,et al.  Control of ascites absorption in anesthetized cats: effects of intraperitoneal pressure, protein, and furosemide diuresis. , 1977, Gastroenterology.